Investing.comDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 18:24:39·⟳ 抓取 18:25:28 +49s·⚡ 决策 10-16 18:29:06 +3m38s·11.2 天前
Omeros 的 narsoplimab（YARTEMLEA）TA-TMA 欧洲上市申请经复审再被 CHMP 否决
复审维持负面意见是预期内的程序性结果（复审翻盘概率本就低），欧洲无当期收入、仅损失远期授权期权；盘前已 -8.4% 完成重定价，且 6 月首次否决的对齐先例显示急跌后快速反弹，追空风险收益比不佳；事件本身为利空不能反手做多。
📄 原文Investing.com↗ 原文
European regulators reject Omeros’ TA-TMA treatment application
Warsh avoids rate guidance; Tesla’s Roadster turns in air - what’s moving markets SEATTLE - Omeros Corporation (NASDAQ:…
不做 Omeros Corporation（OMER.US）
利空方向明确但属预期内的复审维持：欧洲无当期收入，盘前已 -8.4% 基本完成重定价；6 月同标的首次否决后急跌次日即反弹约 14%，此刻 SHORT_AT_OPEN 追空赔率差、易被利空出尽反打；事件为监管否决亦无做多依据，故双向不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CHMP 复审维持否决 narsoplimab 欧洲 TA-TMA 申请，但这一结果自 6 月首次否决后已被高度预期，欧洲业务无当期收入、原计划靠授权第三方变现；盘前约 -8.4% 基本消化，6 月同事件首日 -19% 后次日即反弹约 14%，当前位置做空赔率不足，故不做。
消息传播链
- 公司 10 月 16 日公告收到 CHMP 复审后负面意见，为当事方一手披露，Investing.com 同日 10:24 UTC 转载市场反应:公告后盘前 OMER 跌至约 17.22 美元，较前收 18.79 美元 -8.4%（盘前量约 6600 股，流动性薄）
关键理由
- 欧洲为纯期权价值：美国为唯一商业化市场，欧洲即使获批公司也只计划授权第三方，本次否决不影响当期美国销售与盈利
- 复审维持原判在程序上大概率被预期，叠加终止同情用药（因美国商业需求强劲）这一正面需求信号，盘前 -8.4% 后继续追空的空间有限
主要风险
- 若市场把最终否决解读为该适应症在海外彻底受阻并下调平台估值，开盘后可能继续下跌，做空方向并非没有基本面依据
- 公司 7 月曾遭股东欺诈调查律所征集，存量诉讼/合规噪音可能放大波动，双向都可能被情绪主导
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-12 · 影响 weakens
公司 2026Q2 财报与本次公告均显示美国商业化推进、且因美国商业需求增长而终止同情用药项目，构成对空头的直接反证（需求端健康）
检索:Omeros YARTEMLEA US commercial launch demand Q2 2026 earnings 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-16 · 影响 weakens
欧洲尚无获批疗法、公司原计划获批后才授权第三方，欧洲被否不产生当期收入或现金流损失，只移除远期期权价值
检索:Omeros narsoplimab Europe revenue licensing contribution 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例与盘前报价共同支持不做空：预期内利空、开盘缺口已反映、且同标的历史上急跌后快速反弹；样本仅 1 条、置信区间极宽，不足以支撑反向做多，结论为 AVOID
方向:唯一对齐先例（首次否决）方向为利空：事件日 -19.1%、3 日 -11.3%、5 日 -13.4%（超额 -14.9%），但 K 线显示当日巨阴后次日即 +14% 反弹、5 日内大部分收复，追空在次日开盘即受损
涨幅量级:仅 1 条高相似先例且为意外程度更高的首次否决；本次为预期内的复审维持，盘前 -8.4% 已小于先例的 -19%，剩余向下空间缺乏可靠校准依据
形态:先例呈利空出尽式急跌反弹（gap down 后连续修复），叠加本次公告内含美国需求强劲细节，见利空追高做空的见光死风险落在空头一侧
历史先例(按相似度)
- 相似度 8/10 OMER 2026-06-26 CHMP 首次对 narsoplimab TA-TMA 欧洲申请给出负面意见，当时市场尚未充分定价欧洲失败概率 原文 ↗
事件后 +1日 -19.1% · +2日 -7.6% · +3日 -11.3% · +4日 -12.2% · +5日 -13.4%
⚠未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同一药物、同一适应症、同一监管机构 CHMP；仅阶段为首次负面而非复审维持，意外程度高于本次
经验:首次负面意见当日暴跌约 19%（开盘缺口一度近 -29%），但次日即反弹约 14%，5 个交易日内收回大部分失地，显示该类利空急跌后均值回归明显
工具执行结果 · 成功 7 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 15 ms
{"result": "search_processed_events:agent query=`omer narsoplimab europe rejection october 2026 | omeros narsoplimab ema chmp negative opinion re-examination ta-tma | omeros yartemlea european marketing authorization rejected`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent qu - fetch_decision_experience 成功 stock_tools_inprocess · 1 ms
{ - web_search 成功 doubao_search · 1,856 ms
豆包搜索结果（原始查询:Omeros CHMP negative opinion narsoplimab re-examination October 2026；API SearchType:web） - web_search 成功 doubao_search · 1,596 ms
豆包搜索结果（原始查询:Omeros narsoplimab CHMP negative opinion June 2026 stock reaction；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 1,547 ms
{ - web_search 成功 doubao_search · 1,207 ms
豆包搜索结果（原始查询:"Omeros" "Receives CHMP Negative Opinion Following Re-Examination" October 16 2026；API SearchType:web） - event_study 成功 stock_tools HTTP · 16 ms
{
原文全文
展开原文 · 2,204 字
Warsh avoids rate guidance; Tesla’s Roadster turns in air - what’s moving markets
SEATTLE - Omeros Corporation (NASDAQ:OMER) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the company’s marketing authorization application for narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy following re-examination of its original negative opinion from June 2026.
An eight-member ad hoc expert group consisting of hematologists, statisticians, and transplant physicians, along with two patient representatives, was convened by the committee as part of the re-examination process, according to a press release statement. The committee’s final minutes indicated the expert group recommended a review of individual patient-level data by external experts to better understand factors associated with treatment response and survival. Omeros had submitted patient-level data to the committee in August as part of its re-examination grounds.
The drug was approved under the brand name YARTEMLEA by the U.S. Food and Drug Administration in December 2025 for TA-TMA patients two years of age and older. There is no approved therapy for TA-TMA in Europe.
Omeros is commercializing YARTEMLEA with its own field force in the U.S. market and plans to license commercialization rights to a third party in the European Union if marketing authorization is granted.
The company informed the committee of its intention to terminate the YARTEMLEA compassionate-use program due to increasing demand for drug supply in the U.S. commercial market. Compassionate-use TA-TMA patients currently receiving YARTEMLEA will be provided sufficient drug to complete their treatment courses.
Omeros stated it is working to enable fully reimbursed, named-patient access to YARTEMLEA for those with TA-TMA where permitted in Europe and other regions. The company plans to begin clinical studies in acute respiratory distress syndrome and for prevention of high-risk TA-TMA in pediatric patients later this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SEATTLE - Omeros Corporation (NASDAQ:OMER) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the company’s marketing authorization application for narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy following re-examination of its original negative opinion from June 2026.
An eight-member ad hoc expert group consisting of hematologists, statisticians, and transplant physicians, along with two patient representatives, was convened by the committee as part of the re-examination process, according to a press release statement. The committee’s final minutes indicated the expert group recommended a review of individual patient-level data by external experts to better understand factors associated with treatment response and survival. Omeros had submitted patient-level data to the committee in August as part of its re-examination grounds.
The drug was approved under the brand name YARTEMLEA by the U.S. Food and Drug Administration in December 2025 for TA-TMA patients two years of age and older. There is no approved therapy for TA-TMA in Europe.
Omeros is commercializing YARTEMLEA with its own field force in the U.S. market and plans to license commercialization rights to a third party in the European Union if marketing authorization is granted.
The company informed the committee of its intention to terminate the YARTEMLEA compassionate-use program due to increasing demand for drug supply in the U.S. commercial market. Compassionate-use TA-TMA patients currently receiving YARTEMLEA will be provided sufficient drug to complete their treatment courses.
Omeros stated it is working to enable fully reimbursed, named-patient access to YARTEMLEA for those with TA-TMA where permitted in Europe and other regions. The company plans to begin clinical studies in acute respiratory distress syndrome and for prevention of high-risk TA-TMA in pediatric patients later this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
44d0630c48· 2026-10-16 18:29 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前